Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases

Assem, Hisham, MD*; Rambau, Peter, F., MD*,†; Lee, Sandra, MD*; Ogilvie, Travis, MD*; Sienko, Anna, MD*; Kelemen, Linda, E., ScD‡,§; Köbel, Martin, MD*

The American Journal of Surgical Pathology: April 2018 - Volume 42 - Issue 4 - p 534–544
doi: 10.1097/PAS.0000000000001016
Original Articles

Although infrequently encountered, the diagnosis of ovarian high-grade endometrioid carcinoma remains a diagnostic challenge with potential consequences for targeted therapies and genetic counselling. We studied the clinical, morphologic, and immunohistochemical features of ovarian high-grade endometrioid carcinomas and their diagnostic reproducibility compared with tuboovarian high-grade serous carcinomas. Thirty cases confirmed as International Federation of Gynecology and Obstetrics grade 3 endometrioid carcinomas were identified from 182 ovarian endometrioid carcinomas diagnosed in Alberta, Canada, between 1978 and 2010, from the population-based Alberta Ovarian Tumor Types cohort. Cases of lower grade endometrioid and high-grade serous carcinoma served for comparison. Ten immunohistochemical markers were assessed on tissue microarrays. Clinical data were abstracted and survival analyses performed using Cox regression. Interobserver reproducibility for histologic type was assessed using 1 representative hematoxylin and eosin–stained slide from 25 randomly selected grade 3 endometrioid carcinomas and 25 high-grade serous carcinomas. Histotype was independently assigned by 5 pathologists initially blinded to immunohistochemical WT1/p53 status, with subsequent reassessment unblinded to WT1/p53 status. Patients diagnosed with grade 3 endometrioid carcinoma had a significantly longer survival compared with high-grade serous carcinoma in univariate analysis (hazard ratio [HR]=0.34, 95% confidence interval [CI]=0.16-0.67, P=0.0012) but not after adjusting for age, stage, treatment center, and residual tumor (HR=1.01, 95% CI=0.43-2.16, P=0.98). Grade 3 endometrioid carcinoma cases (N=30) were identical to grade 2 endometrioid carcinoma cases (N=23) with respect to survival in univariate analysis (HR=1.07, 95% CI=0.39-3.21, P=0.89) and immunohistochemical profile. Using histomorphology alone, interobserver agreement for the diagnosis of grade 3 endometrioid or high-grade serous carcinoma was 69%, which significantly increased (P<0.0001) to 96% agreement with the knowledge of WT1/p53 status. Our data support the diagnostic value of WT1/p53 status in differentiating between grade 3 endometrioid carcinoma and high-grade serous carcinoma. However, grade 3 and grade 2 endometrioid carcinomas showed no differences in immunophenotype or clinical parameters, suggesting that they could be combined into a single group.

*Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada

Department of Pathology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania

Department of Public Health Sciences, College of Medicine

§Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

Conflicts of Interest and Source of Funding: Supported by the Cancer Research Society (19319) and CLS internal research support RS11-508. The AOVT study was supported by the Canadian Institutes of Health Research (MOP-86727). P.F.R. was supported by a Thomas E. Feasby PhD student fund. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Martin Köbel, MD, Department of Pathology and Laboratory Medicine, University of Calgary, #7564—1403 29th St. NW, Foothill Medical Center, Calgary, AB, Canada T2N 2T9 (e-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.